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Background: HDL-C raising and LDL-C lowering are believed to reduce risk for vascular disease. The effects of these therapies on lipoprotein 
particle numbers have not been well studied in Type II hyperlipidemia (T2HLP).
Methods: This analysis of a 24-wk, multicenter, randomized, double-blind study included adults with T2HLP who received Ezetimibe/Simvastatin 
(E/S, 10/20 mg), Extended-Release Niacin (N) or the combination (E/S + N). N was titrated over 12 wks to 2 g/d. HDL and LDL particle number 
(HDLp, LDLp) were measured with NMR spectroscopy (LipoScience).
Results: Changes in lipid measures between baseline and 24 weeks were analyzed for 577 participants (n=124 N only, 160 E/S only, 293 E/S+N). 
HDLp increased the most and LDLp decreased to the greatest degree with E/S+N, which differed significantly from N or E/S (Table). In tertile (T1/
T2/T3) analyses those with the lowest HDLp had the greatest percent increase in HDLp ([T1/T2/T3] N: [18.4/7.9/2.1], E/S: [19.3/12.2/5.3], and 
E/S+N: [26.9/13.8/6.9]. The highest tertile of LDLp had the greatest percent reduction in LDLp (N: [18.3/23.1/24.6], E/S: [29.7/38.3/41.8], and 
E/S+N: [44.3/ 49.0/ 50.5]). HDLp and LDLp tertile results were significant at p<0.001 for all treatment groups. 
Treatment
HDL-C
Baseline
Mean (SD)
(mg/dL)
HDLp Baseline
Mean (SD)
(umol/L)
HDLp Change
(significance*)
LDL-C Baseline
Mean (SD)
(mg/dL)
LDLp Baseline
Mean (SD)
(nmol/L)
LDLp Change
(significance*)
N
49.8
(13.7)
32.0
(6.0)
+9.8% (p<0.001) 158 (22.1)
1729
(335)
-21.5%
(p<0.001)
E/S
48.4
(12.8)
32.0
(6.0)
+12.8% (p<0.03) 156 (21.3)
1758
(332)
-36.8%
(p<0.03)
E/S+N
46.7
(12.1)
32.3
(6.1)
+16.2%
referent
156 (22.9)
1722
(302)
-47.7%
(referent)
*Statistical difference relative to E/S +N group.
Conclusions: Combination therapy with E/S+N increased HDLp and reduced LDLp more than E/S or N alone in persons with T2HLP. The greatest 
changes in HDLp ad LDLp occurred in those subjects with the lowest HDLp and highest LDLp at baseline.
